Archaea as emerging, fastidious members of the human microbiota  by Drancourt, M.
Archaea as emerging, fastidious members of the human microbiota
M. Drancourt
Unite´ de Recherche sur les Maladies Infectieuses et Tropicales Emergentes UMR CNRS 6236 IRD 198, FR IDMM, Me´diterrane´e Infection, Aix-Marseille-Uni-
versite´, Marseille, France
E-mail: michel.drancourt@univmed.fr
Article published online: 25 May 2012
It was only approximately 20 years ago that the noun Ar-
chaea entered the lexicon of clinical microbiology, when it
became increasingly apparent that these prokaryotic organ-
isms, which form one of the four domains of life, were pres-
ent in the human and animal microbiota [1]. Found in harsh
environments, archaeons were initially tagged as extremo-
philes, a term that prevented microbiologists from thinking
of them in terms of clinical microbiology. The window
opened for the Archaea to be viewed differently when one
organism that forms methane in the mammalian gut, later
named Methanobrevibacter smithii, was found to be an archa-
eon [2]. Methane-forming archaeons, named methanogens,
are now recognized as members of the mammal and human
gut microbiota; four such methanogens have been cultured,
as reviewed by Be´dis Dridi [3]. In fact, methanogens are fas-
tidious organisms; the isolation and culture of the species
Methanomassilicoccus luminyensis took more than 1 year [4].
In the review, Be´dis Dridi further states that methanogens
often escape routine detection, for three main reasons:
microscopic examination is non-speciﬁc; the culturing of
methanogens requires an unusual atmosphere consisting of
hydrogen; and PCR-based detection requires speciﬁc primers
and probes. Nevertheless, several clinical microbiology teams
have detected methanogens within the oral, gut and vaginal
microbiota with potential roles in some diseases, including
obesity, as reviewed by Mayer and collaborators. There is
now strong evidence implicating the methanogen Methano-
brevibacter oralis [5] in periodontopathy. In this situation,
M. oralis has a ‘maﬁa’ strategy, as its survival is completely
dependent on anaerobes, which provide it with hydrogen.
Because of this complete dependency on anaerobes, which
are highly susceptible to metronidazole [6], showing that oral
metronidazole suppressed the major gut methanogen M. smi-
thii [7] was somewhat difﬁcult. Here, Saber Khelaiﬁa and I
[8] show that, indeed, M. smithii and other methanogens are
susceptible to metronidazole and related ornidazole deriva-
tives, which, along with fusidic acid, are the only known
effective antibiotics for the treatment of potential methano-
gen infections. Indeed, methanogens illustrate a paradigm that
the archaeons are susceptible to compounds that are also
effective against both bacteria and eukaryotes [9]. Methano-
gens, chieﬂy M. oralis, are also susceptible to topical com-
pounds used as local treatments for periodontopathy. As
reviewed by Dridi [3], as well as Mayer and collaborators
[10], non-methanogenic archaeons, including halophilic archa-
eons, have been detected by PCR-based methods in the
human gut microbiota,. Interestingly, it has been shown that
such organisms could be healthcare-related organisms deliv-
ered with the purgative administered before colonoscopy
[11]. This observation indicates that further work is war-
ranted to precisely establish the susceptibility of archaeons,
including to the biocides that are used for the decontamina-
tion of colonoscopes. Additionally, the availability of a few
human archaeal genomes (more than 20 M. smithii genomes
are available [12], and the fact that our group has genome-
sequenced M. luminyensis [4]), should prompt the develop-
ment of additional molecular methods for the detection and
genotyping of archaeons in the human microbiota. Genotyp-
ing will help to provide an understanding of the sources of
human archaeons and their dynamics in the microbiota.
Finally, in vitro susceptibility data lead to questioning of the
effectiveness of current protocols for the decontamination of
colonoscopes. Microbiology terminology informs the way in
which microbiologists think about microbes, and clinical mi-
crobiologists should be aware that the word Archaea is inap-
propriate as a name to encompass the wide variety of these
organisms, as they have been revealed to be common and
not at all archaeal; rather, they now must be regarded as
emerging and fastidious organisms.
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